SolasCure has announced the successful completion of its Phase IIb clinical trial, CLEANVLU2. The Cambridge-based biotechnology company is developing a novel treatment, Aurase Wound Gel (AWG), to ...
Here's Why. Ethereum remains a focal point for institutional on-chain activity even as price momentum stalls. In 2026, Ether has retreated about 36% for the year, slipping back from the $3,000 milesto ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results